Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
For those who have tried unsuccessfully to use a CPAP machine to treat sleep apnea, the Inspire implant is a breakthrough ...
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...
T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by ...
Various medical devices are available to help treat sleep apnea. Choosing the right one comes down to the severity of your condition, your personal preferences, and your lifestyle. Sleep apnea is ...
The FDA approved Eli Lilly's (LLY) obesity drug for the treatment of sleep apnea, sending rival ResMed (RMD) stock lower ...
ResMed's Chief Medical Officer has suggested doctors will prescribe using both drugs and devices such as his company makes together to help sleep apnea suffers. Shares of ResMed (RMD) and Inspire ...
device, which is currently one of the standard treatments for obstructive sleep apnea. That group was compared to one taking a placebo and using PAP. “This is the first pharmacologic therapy ...
The sleep screening devices market is projected to grow from US$ 9,298 million in 2023 to US$ 17,564.5 million by 2033, at a ...
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...
The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback